.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
US Department of Justice
Covington
Express Scripts
Mallinckrodt
UBS
Cantor Fitzgerald
Argus Health
Chinese Patent Office
Chubb

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,589,960

« Back to Dashboard

Which drugs does patent 6,589,960 protect, and when does it expire?


Patent 6,589,960 protects PALLADONE, DILAUDID, and DILAUDID-HP, and is included in four NDAs. There have been zero Paragraph IV challenges on Dilaudid and Dilaudid-HP

This patent has seventeen patent family members in nine countries.

Summary for Patent: 6,589,960

Title: Hydromorphone and hydrocodone compositions and methods for their synthesis
Abstract:A method for the preparation of a ketone from a narcotic alkaloid having an allyl alcohol moiety is disclosed. The method includes mixing the narcotic alkaloid with an acid in the presence of a catalyst wherein the method is carried out in the substantial absence of hydrogen gas. The method is useful for preparing hydromorphone and hydrocodone compositions having novel impurity profiles. Compositions comprising hydromorphone and hydrocodone are also disclosed.
Inventor(s): Harclerode; William H. (Asbury, NJ), Gault; Robert (Gross Pointe Woods, MI), Sandison; Mark D. (Dearborn, MI)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/256,996
Patent Claim Types:
see list of patent claims
Composition; Process; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Purdue Pharma LpPALLADONEhydromorphone hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL021044-001Sep 24, 2004DISCNNoNo► Subscribe► Subscribe► SubscribeY
Purdue Pharma LpPALLADONEhydromorphone hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL021044-002Sep 24, 2004DISCNNoNo► Subscribe► Subscribe► SubscribeY
Purdue Pharma LpPALLADONEhydromorphone hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL021044-003Sep 24, 2004DISCNNoNo► Subscribe► Subscribe► SubscribeY
Purdue Pharma LpPALLADONEhydromorphone hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL021044-004Sep 24, 2004DISCNNoNo► Subscribe► Subscribe► SubscribeY
Fresenius Kabi UsaDILAUDIDhydromorphone hydrochlorideINJECTABLE;INJECTION019034-003Apr 30, 2009APRXYesYes► Subscribe► Subscribe► SubscribeYY
Fresenius Kabi UsaDILAUDIDhydromorphone hydrochlorideINJECTABLE;INJECTION019034-004Apr 30, 2009APRXYesYes► Subscribe► Subscribe► SubscribeYY
Fresenius Kabi UsaDILAUDIDhydromorphone hydrochlorideINJECTABLE;INJECTION019034-005Apr 30, 2009APRXYesYes► Subscribe► Subscribe► SubscribeYY
Fresenius Kabi UsaDILAUDID-HPhydromorphone hydrochlorideINJECTABLE;INJECTION019034-001Jan 11, 1984APRXYesYes► Subscribe► Subscribe► SubscribeY
Fresenius Kabi UsaDILAUDID-HPhydromorphone hydrochlorideINJECTABLE;INJECTION019034-002Aug 4, 1994DISCNNoNo► Subscribe► Subscribe► SubscribeY
Rhodes PharmsDILAUDIDhydromorphone hydrochlorideSOLUTION;ORAL019891-001Dec 7, 1992AARXYesYes► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,589,960

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,512,117 Hydromorphone and hydrocodone compositions and methods for their synthesis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,589,960

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria402937► Subscribe
Austria500257► Subscribe
Australia1595701► Subscribe
Canada2389193► Subscribe
Canada2674424► Subscribe
Canada2854796► Subscribe
Germany60039711► Subscribe
Germany60045695► Subscribe
European Patent Office1233966► Subscribe
European Patent Office2003134► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Colorcon
Chubb
Boehringer Ingelheim
Healthtrust
Federal Trade Commission
Fuji
US Department of Justice
Daiichi Sankyo
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot